What we found on the web about Charcot
Jean-Martin Charcot - Wikipedia, the free encyclopedia
Jean-Martin Charcot (29 November 1825 – 16 August 1893) was a French neurologist and professor of anatomical pathology. [1] He is known as "the founder of modern neurology" and ...
Charcot-Marie-Tooth disease - Wikipedia, the free encyclopedia
Charcot-Marie-Tooth disease (CMT), known also as Hereditary Motor and Sensory Neuropathy (HMSN), Hereditary Sensorimotor Neuropathy (HSMN), or Peroneal Muscular Atrophy, is a ...
Charcot Marie Tooth Disease - CMT Disease - Hereditary Neuropathy
The Hereditary Neuropathy Foundation raises awareness, funds scientific research, and educates the medical community and the general public about Charcot Marie Tooth Disease, CMT ...
Antarctic Explorers: Jean-Baptiste Charcot
Captain Scott called him the "polar gentleman". The two men originally met on the slopes of Mont Ventoux where both were training for the next polar ...
Charcot's Joint - Symptoms, Treatment and Prevention
Symptoms, Treatment and Prevention of Charcot's Joint ... Definition of Charcot's Joint; Description of Charcot's Joint; Causes and Risk Factors of Charcot's Joint
Charcot - definition of Charcot in the Medical dictionary - by the ...
Char·cot (shär-k), Jean Martin 1825-1893. French neurologist. A teacher of Sigmund Freud and Alfred Binet, he is known for his investigations of nervous diseases, his work on ...
Charcot-Marie-Tooth Disease: eMedicine Orthopedic Surgery
Overview: Charcot-Marie-Tooth (CMT) disease is the most common inherited neurologic disorder. CMT is characterized by inherited neuropathies without known metabolic derangements ...
Charcot-Marie-Tooth Disease Fact Sheet: National Institute of ...
What is Charcot-Marie-Tooth disease? What are the symptoms of Charcot-Marie-Tooth disease? What are the types of Charcot-Marie-Tooth disease? What causes Charcot-Marie-Tooth ...
European Charcot Foundation - Organisation for the advancement of ...
The European Charcot Foundation is a non-profit, independent organisation for the advancement of Multiple Sclerosis Research in Europe, sponsored by private organisations, Multiple ...
THE CHARCOT FOOT
Charcot's original description of neurogenic arthropathy in 1869 was limited to patients with syphilis. Since that time, conditions other than syphilis have been found to cause a ...
A Science Odyssey: People and Discoveries: Jean-Martin Charcot
Jean-Martin Charcot 1825 - 1893. Jean-Martin Charcot was born in Paris, France, late in 1825. Although he was a nineteenth century scientist, his influence carried on into the next ...
Charcot-Marie-Tooth disease - Wikipedia, the free encyclopedia
Charcot-Marie-Tooth disease (CMT), known also as Hereditary Motor and Sensory Neuropathy (HMSN), Hereditary Sensorimotor Neuropathy (HSMN), or Peroneal Muscular Atrophy, is a ...
Entry added by Creative Administrator
Creative Administrator also edited:
Here is what users have to say about Charcot

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!
These recent articles mention Charcot
Breast cancer patients treated with chemotherapy drug Taxol more likely to develop chronic neuropathic pain
News-Medical-Net
Breast cancer patients treated with the chemotherapy drug Taxol (paclitaxel) are more likely to develop chronic neuropathic pain, according to research published in The Journal of Pain, the peer review publication of the American Pain Socie...
Genetics: Genetic testing
Nursing Times
For example there are more than 20 genes associated with a group of progressive peripheral neuropathies collectively referred to as Charcot-Marie-Tooth disease and more than 10 associated with Long QT syndrome (an inherited arrhythmia).
Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced
News-Medical-Net
Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE)....